



ASX and Media Release

Viralytics Commences Trading on US OTCQX Marketplace

OTCQX Symbol VRACY

5th August 2013, Sydney, Australia: Viralytics Ltd (ASX: VLA; OTCQX: VRACY) is pleased to announce that its American Depositary Receipts (ADRs) have commenced trading on OTCQX International, a segment of the OTCQX marketplace. ADRs trade under the symbol "VRACY" and each ADR represents 3 ordinary shares. Viralytics will continue to trade on the ASX under its existing symbol "VLA."

OTCQX International is a segment of the OTCQX marketplace reserved for high-quality non-U.S. companies that are listed on a qualified international exchange, undergo management reviews and provide their home country disclosure to U.S. investors. It provides US based investors and other groups ready access to company information and announcements that will be released contemporaneously with the ASX. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

Roth Capital Partners, LLC will act as Principal American Liaison to the company, providing guidance on OTCQX matters including disclosure requirements. Headquartered in California with other international offices, Roth Capital is an investment banking firm specialising in small-caps with a focus on the healthcare sector.

"We are pleased to be able to take this step to increase our profile in the United States at such an exciting stage in the development of CAVATAK™. Trading on OTCQX is part of a broader strategy to promote the company and our technology in the United States. Whilst joining OTCQX is a logical next step in the growth of Viralytics, we remain committed to our ASX listing and Australian investors who continue to support the company," said CEO of Viralytics, Dr Malcolm McColl.

Enquiries:
Dr Malcolm McColl
02 9988 4000

Rudi Michelson
Monsoon Communications
03 9620 3333

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers. Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CVA21 binds to specific 'receptor' proteins highly expressed on multiple cancer types including, but not limited to: melanoma; prostate, lung, breast and bladder cancers; and multiple myeloma. CAVATAK™ acts to kill both local and



metastatic cancer cells, by direct cytolysis and a possible immune response. The preferential targeting of cancer rather than healthy cells provides the potential for low toxicity in the patient. The company is actively enrolling a phase II clinical trial, of intratumourally administered CAVATAK™ in the treatment of Late stage Melanoma (the CALM study), at multiple prestigious cancer clinics in the US. Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. The second stage of the STORM trial will include combination treatments with existing chemotherapies in one of the above cancer types. Subject to regulatory approval the STORM trial will commence at three prominent UK sites later in 2013.

Based in Sydney Australia, the company is listed on the Australian Securities Exchange (ASX: VLA) while Viralytics' ADRs also trade under the symbol "VRACY" on the US OTCQX marketplace (OTCQX: VRACY).